← Leaderboards
Theresa E Hahn
Roswell Park Cancer Institute Corp
$4,613,853
Attributed
$10,523,236
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,523,236 · 5
By mechanism
R01$10,347,736 · 4
R03$175,500 · 1
Top collaborators
- Lara Sucheston-Campbell6 shared
- Alyssa Ione Clay-Gilmour5 shared
- Qianqian Zhu5 shared
- Marcelo C. Pasquini4 shared
- Charles Stewart Kamen1 shared
- Lori Sakoda1 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Protul Shrikant$4,542,208
- Lara Sucheston-Campbell$2,575,366
- Qianqian Zhu$1,921,800
- Alyssa Ione Clay-Gilmour$1,711,362
- Xuefang Cao$8,586,764
Others in their field
Top investigators on “Clinical Practice”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Barton F Haynes · Duke University$350,843,251
- Larry Arthur$256,560,682
- Steven E Reis · University Of Pittsburgh At Pittsburgh$239,432,250
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$237,082,372
Research focus
Clinical PracticeTransplantationBloodAffectGenotypeGenome Wide Association StudyGeneticGenetic VariantHematologic NeoplasmsGenesResourcesMalignant NeoplasmsCohortBaseTranslatingChemotherapyExposure ToFundingAmericanBone Marrow TransplantationLifeHematological DiseaseMarrowSampling
Grant awards (16)
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors$766,294
R01 · FY2025 · CA · contact PI
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation$605,569
R01 · FY2025 · CA · contact PI
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation$593,753
R01 · FY2024 · CA · contact PI
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation$503,068
R01 · FY2023 · CA · contact PI
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation$463,641
R01 · FY2022 · CA · contact PI
Multi-ethnic high-throughput study to identify novel non-HLA genetic contributors to mortality after blood and marrow transplantation$954,265
R01 · FY2021 · CA · contact PI
Genetic susceptibility to acute lymphocytic and myeloid leukemia$87,750
R03 · FY2016 · CA · contact PI
Genetic susceptibility to acute lymphocytic and myeloid leukemia$87,750
R03 · FY2015 · CA · contact PI
Ancillary Studies in Clinical Trials - PRIMeR$370,927
R01 · FY2014 · HL
Genetic susceptibility to unrelated donor stem cell transplant-related mortality$472,096
R01 · FY2013 · HL · contact PI
Ancillary Studies in Clinical Trials - PRIMeR$354,238
R01 · FY2013 · HL
Genetic susceptibility to unrelated donor stem cell transplant-related mortality$1,214,404
R01 · FY2012 · HL · contact PI
Ancillary Studies in Clinical Trials - PRIMeR$366,611
R01 · FY2012 · HL
Genetic susceptibility to unrelated donor stem cell transplant-related mortality$1,704,501
R01 · FY2011 · HL · contact PI
Ancillary Studies in Clinical Trials - PRIMeR$394,139
R01 · FY2011 · HL
Genetic susceptibility to unrelated donor stem cell transplant-related mortality$1,584,230
R01 · FY2010 · HL · contact PI